Recent advances in the understanding and treatment of acute myeloid leukemia

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations


Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.

Original languageEnglish (US)
Article number1196
StatePublished - 2018


  • Acute myeloid leukemia (AML); genomics; epigenetics; targeted therapies; drug development

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Recent advances in the understanding and treatment of acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this